首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >Immunological inhibition of transplanted liver allografts by adeno-associated virus vector encoding CTLA4Ig in rats
【24h】

Immunological inhibition of transplanted liver allografts by adeno-associated virus vector encoding CTLA4Ig in rats

机译:编码CTLA4Ig的腺相关病毒载体对大鼠同种异体移植肝的免疫抑制作用

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Blockade interaction between CD28 and B7 with CTLA4Ig has been shown to induce experimental transplantation tolerance. In order to prolong the inhibitory effect of CTLA4Ig, a recombinant adeno-associated virus vector pSNAV expressing CTLA4Ig was constructed, and its effects on transplanted liver allografts were investigated. METHODS:The pSNAV-CTLA4Ig construct was infused into partial liver allografts of rats via the portal vein during transplantation. CTLA4Ig expression in the transplanted livers was detected with reverse transcriptase-polymerase chain reaction (RT-PCR) analysis and immunohistochemistry. Furthermore, real-time quantita-tive PCR was used to measure the expression of IL-2, IFN-γ, IL-4 and IL-10 in the allografts. RESULTS:The expression of CTLA4Ig in the partial allograft was detected successfully and pSNAV-CTLA4Ig improved the survival rate of rats after liver transplantation. Agarose gel analysis of RT-PCR products indicated the presence of CTLA4Ig in the pSNAV-CTLA4Ig treatment group. Cytokines expressed in allografts on day 7 after orthotopic liver transplantation showed that IL-2, IFN-γ, IL-4 and IL-10 mRNA levels decreased in transplant recipients treated with pSNAV-CTLA4Ig compared with those treated with pSNAV-LacZ (1.62±0.09, 1.52±0.11, 1.50± 0.07 and 1.43±0.07 versus 1.29±0.09, 1.32±0.07, 1.34±0.06 and 1.35±0.04, respectively). CONCLUSIONS:pSNAV-CTLA4Ig effectively expressed CTLA4Ig in liver allografts. CTLA4Ig improved the pathological ifndings after liver transplantation. CTLA4Ig induced immune tolerance of liver transplantation, and the mechanism involved induced alteration of Th1 and Th2 cytokine transcripts. The adeno-associated virus vector encoding CTLA4Ig may be useful in the clinical study of transplantation tolerance.
机译:背景:已证明CD28和B7与CTLA4Ig之间的阻断相互作用可诱导实验性移植耐受。为了延长CTLA4Ig的抑制作用,构建了表达CTLA4Ig的重组腺相关病毒载体pSNAV,并研究了其对移植肝移植的影响。 方法:将pSNAV-CTLA4Ig构建体在移植过程中通过门静脉注入大鼠部分肝移植物中。通过逆转录聚合酶链反应(RT-PCR)分析和免疫组化检测CTLA4Ig在移植肝脏中的表达。此外,实时定量PCR用于测量同种异体移植物中IL-2,IFN-γ,IL-4和IL-10的表达。 结果:成功检测了部分同种异体移植物中CTLA4Ig的表达,pSNAV-CTLA4Ig提高了大鼠肝移植后的存活率。 RT-PCR产物的琼脂糖凝胶分析表明在pSNAV-CTLA4Ig治疗组中存在CTLA4Ig。原位肝移植后第7天在同种异体移植物中表达的细胞因子表明,与pSNAV-LacZ处理的移植受者相比,pSNAV-CTLA4Ig处理的移植受者的IL-2,IFN-γ,IL-4和IL-10 mRNA水平降低(1.62±分别为0.09、1.52±0.11、1.50±0.07和1.43±0.07,而1.29±0.09、1.32±0.07、1.34±0.06和1.35±0.04)。 结论:pSNAV-CTLA4Ig在肝移植物中有效表达CTLA4Ig。 CTLA4Ig改善了肝移植后的病理发现。 CTLA4Ig诱导肝移植的免疫耐受,其机制涉及诱导Th1和Th2细胞因子转录本的改变。编码CTLA4Ig的腺相关病毒载体可用于移植耐受性的临床研究。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2008年第003期|258-263|共6页
  • 作者单位

    Center of Liver Transplantation, First Afifliated Hospital, Nanjing Medical University, Nanjing 210029, China;

    Center of Liver Transplantation, First Afifliated Hospital, Nanjing Medical University, Nanjing 210029, China;

    Center of Liver Transplantation, First Afifliated Hospital, Nanjing Medical University, Nanjing 210029, China;

    Center of Liver Transplantation, First Afifliated Hospital, Nanjing Medical University, Nanjing 210029, China;

    Center of Liver Transplantation, First Afifliated Hospital, Nanjing Medical University, Nanjing 210029, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号